Splice-Switching Antisense Oligonucleotides as a Targeted Intrinsic Engineering Tool for Generating Armored Redirected T Cells.
HBV+HCC
TCR-redirected T cells
splice switching antisense oligonucleotides (SSOs)
Journal
Nucleic acid therapeutics
ISSN: 2159-3345
Titre abrégé: Nucleic Acid Ther
Pays: United States
ID NLM: 101562758
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
pubmed:
11
2
2021
medline:
23
11
2021
entrez:
10
2
2021
Statut:
ppublish
Résumé
Modification of specificity of T cells for the use in adoptive transfer (CAR- or TCR-redirected T cells) has revolutionized the therapy of liquid tumors and some infectious diseases. However, several obstacles are still hampering the efficacy of such potent therapy, hence concurrent modification of the function is also required to obtain successful results. Here we show the use of splice-switching antisense oligonucleotides (SSOs) as a tool to transiently modify T cell function. We demonstrate the possibility to transfect SSOs and an exogenous TCR into primary human T cells in the same electroporation reaction, without affecting viability and function of the transfected T lymphocytes. Moreover, we show that SSOs targeting T cell-specific mRNAs induce the skipping of the targeted exons, and the reduction of the protein and consequent modification of T cell function. This technical work paves the way to the use of SSOs in immune cells, not only for the knockdown of the functional isoform of the targeted proteins, but also for the protein manipulation by elimination of specific domains encoded by targeted exons.
Identifiants
pubmed: 33567222
doi: 10.1089/nat.2020.0905
pmc: PMC7997720
doi:
Substances chimiques
Oligonucleotides, Antisense
0
RNA, Messenger
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM